A pharma giant is moving past one patent cliff — but another is already looming
Summary
Novartis is facing difficulties in developing its next wave of major medicines. Recent clinical trial setbacks and disappointing data highlight the pharmaceutical company's struggles to overcome upcoming losses from expiring patents.
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.